Efstathiou Discusses Impact of Niraparib Combo From MAGNITUDE in mCRPC
March 2nd 2022Eleni Efstathiou, MD, PhD, spoke about how results of the phase 3 MAGNITUDE trial, which examined the combination of niraparib with abiraterone acetate and prednisone, have the ability to change the standard of care in patients with metastatic castration-resistant prostate cancer.
Efstathiou Discusses Positive Outcomes in HRR+ mCRPC With Niraparib Combo in MAGNITUDE Trial
February 25th 2022Eleni Efstathiou, MD, PhD, spoke about the positive results seen in the phase 3 MAGNITUDE trial in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations who were treated with a niraparib-containing regimen.
2-Minute Drill: Experts Discuss 2022 Genitourinary Cancers Symposium
February 24th 2022Following 2022 ASCO GU, Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, engage in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics include most surprising new data, what needs follow-up, and shameless plug.